UK Markets close in 42 mins
  • FTSE 100

    6,362.08
    -0.85 (-0.01%)
     
  • FTSE 250

    19,251.65
    -144.69 (-0.75%)
     
  • AIM

    1,040.31
    +2.28 (+0.22%)
     
  • GBP/EUR

    1.1180
    -0.0031 (-0.28%)
     
  • GBP/USD

    1.3360
    +0.0004 (+0.0267%)
     
  • BTC-GBP

    12,402.30
    -278.82 (-2.20%)
     
  • CMC Crypto 200

    324.18
    -13.31 (-3.94%)
     
  • S&P 500

    3,643.03
    +13.38 (+0.37%)
     
  • DOW

    29,940.24
    +67.77 (+0.23%)
     
  • CRUDE OIL

    45.26
    -0.45 (-0.98%)
     
  • GOLD FUTURES

    1,785.50
    -25.70 (-1.42%)
     
  • NIKKEI 225

    26,644.71
    +107.40 (+0.40%)
     
  • HANG SENG

    26,894.68
    +75.23 (+0.28%)
     
  • DAX

    13,353.50
    +66.93 (+0.50%)
     
  • CAC 40

    5,603.85
    +37.06 (+0.67%)
     

Global Netherton Syndrome Market Forecast to 2027 - COVID-19 Impact and Analysis

Research and Markets
·7-min read

Dublin, Nov. 02, 2020 (GLOBE NEWSWIRE) -- The "Netherton Syndrome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapy (Keratolytic Agents, Oral and Topical Steroids and Retinoids, Topical Calcineurin Inhibitors, Radiation Therapy, and Biological Therapy), and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the global Netherton syndrome market is expected to reach US$ 74.31 million by 2027 from US$ 19.57 million in 2019; it is estimated to grow at a CAGR of 20.3% from 2020 to 2027. The report highlights trends prevailing in the global Netherton syndrome market, and the drivers and hindrances pertaining to the market growth.

Netherton syndrome is a rare disorder characterized by trichorrhexis invaginata, atopic diathesis, and ichthyosiform erythroderma. The trichorrhexis invaginata indicates short and brittle hair, atopic diathesis represents susceptibility to allergy problems while ichthyosiform erythroderma encompasses red, inflamed, scaly skin. Netherton syndrome is hereditary as it is an autosomal recessive trait. The disease is majorly caused due to mutations associated with SPINK5 gene. In some cases, although there is no family history of the disease, the syndrome is revealed even when two healthy parents that carry the mutated recessive gene have a child, which receives both copies of the recessive gene.

Based on therapy, the global Netherton syndrome market is segmented into keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, biological therapies, and radiation therapies. In 2019, the keratolytic agents segment held the largest share of the global Netherton syndrome market. However, the biological therapy segment is estimated to register the highest CAGR in the market during the forecast period. The growth of the market for the biological therapy segment is attributed to the increasing adoption of biological therapy due to its beneficial treatment outcomes.

Lifemax Laboratories, Inc.; Azitra, Inc.; Sixera Pharma Ab; Dermelix Biotherapeutics; Matrisys Bioscience; Quoin Pharmaceuticals Ltd.; and Krystal Biotech, Inc. are a few of the leading companies operating in the Netherton syndrome market.

The report segments the global Netherton syndrome market as follows:

By Therapy

  • Keratolytic Agents

  • Oral and Topical Steroids and Retinoid

  • Topical Calcineurin Inhibitors

  • Radiation Therapies

  • Biological Therapies

By Geography

North America

  • US

  • Canada

  • Mexico

Europe

  • France

  • Germany

  • UK

  • Spain

  • Italy

  • Rest of Europe

Asia Pacific (APAC)

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • Rest of APAC

Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • South Africa

  • Rest of MEA

  • South and Central America (SCAM)

  • Brazil

  • Argentina

  • Rest of SCAM

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Netherton syndrome market.

  • Highlights key business priorities in order to assist companies to realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the global Netherton syndrome market, thereby allowing players across the value chain to develop effective long-term strategies.

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Global Netherton Syndrome Market - By Epidemiology
1.3.2 Global Netherton Syndrome Market - By Therapy
1.3.3 Global Netherton Syndrome market - By Geography

2. Netherton Syndrome Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
3.4 Expert Opinions

4. Global Netherton Syndrome Market - Disease Background And Overview
4.1 Introduction
4.2 Causes and Pathophysiology
4.3 Ages
4.4 Risk Factors
4.5 Diagnosis
4.6 Epidemiology

5. Netherton Syndrome Market- Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Number of Awareness Campaigns
5.1.2 Increasing Drug Launches and Robust Pipeline
5.2 Market Restraint
5.2.1 Side-Effects Associated with Netherton Syndrome Drugs
5.3 Market Opportunity
5.3.1 Growth Opportunities in Developing Economies
5.4 Impact Analysis of Drivers and Restraints

6. Netherton Syndrome Market - Global Analysis
6.1 Global Netherton Syndrome Market Revenue Forecast and Analysis
6.2 Global Netherton Syndrome Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players

7. Netherton Syndrome Market Analysis - By Epidemiology
7.1 Overview
7.2 Prevalent Cases
7.2.1 Overview
7.3 Diagnosed Cases
7.3.1 Overview
7.4 Gender-Specific Cases
7.4.1 Overview
7.5 Drug-Treatable Cases
7.5.1 Overview

8. Netherton Syndrome Market Analysis - By Therapy
8.1 Overview
8.2 Netherton Syndrome Market Revenue Share, by Therapy (2019 and 2027)
8.3 Keratolytic Agents
8.3.1 Overview
8.3.2 Keratolytic Agents: Netherton Syndrome Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Biological Therapies
8.4.1 Overview
8.4.2 Biological Therapies: Netherton Syndrome Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Oral and Topical Steroids and Retinoids
8.5.1 Overview
8.5.2 Oral and Topical Steroids and Retinoids: Netherton Syndrome Market - Revenue and Forecast to 2027 (US$ Million)
8.6 Topical Calcineurin Inhibitors
8.6.1 Overview
8.6.2 Topical Calcineurin Inhibitors: Netherton Syndrome Market - Revenue and Forecast to 2027 (US$ Million)
8.7 Radiation Therapy
8.7.1 Overview
8.7.2 Radiation Therapy: Netherton Syndrome Market - Revenue and Forecast to 2027 (US$ Million)

9. Netherton Syndrome Market- Geographic Analysis
9.1 North America: Netherton Syndrome Market
9.2 Europe: Netherton Syndrome Market
9.3 Asia Pacific: Netherton Syndrome Market

10. Netherton Syndrome Market - Treatment and Emerging Therapies
10.1 Treatment Paradigm
10.2 Emerging Therapies
10.3 Clinical Trials by Phase
10.4 Attribute Analysis (Marketed and Upcoming Therapies)

11. Company Profiles
11.1 LIFEMAX LABORATORIES
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Azitra Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Sixera Pharma (Gozinto )
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Dermelix Biotherapeutics
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 MATRISYS BIOSCIENCE
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Quoin Pharmaceuticals Ltd.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Krystal Biotech
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments

12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/ac3eme

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900